Related Experiment Video

Updated: Jun 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

[Genetics and hepatitis C treatment: towards a personalized treatment?]

Sabela Lens García1, Mairene Coto-Llerena, Sofía Pérez del Pulgar Gallart

  • 1Servicio de Hepatología, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, Barcelona, España.

Gastroenterologia Y Hepatologia
|March 23, 2011
PubMed

Insights

Genetic variations near the IL28B gene significantly predict treatment success for chronic hepatitis C virus (HCV) infection. Understanding these host genetics improves patient management and treatment strategies for liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Genetics

Background:

  • Chronic hepatitis C virus (HCV) infection leads to liver cirrhosis and cancer, a major cause of liver transplantation.
  • Current treatments (pegylated interferon and ribavirin) have limited efficacy, with only 50% achieving sustained virological response.
  • Host and viral factors influence treatment outcomes in chronic hepatitis C.

Purpose of the Study:

  • To review recent genetic studies on hepatitis C treatment response.
  • To discuss the clinical implications of host genetic variations, particularly IL28B polymorphisms.
  • To highlight the growing role of genetics in managing liver diseases.

Main Methods:

  • Review of recent genetic studies focusing on IL28B gene polymorphisms.
  • Analysis of the predictive value of these polymorphisms for HCV clearance and treatment response.
  • Synthesis of clinical implications for liver disease management.

Main Results:

  • Polymorphisms near the IL28B gene are strong predictors of spontaneous HCV clearance.
  • IL28B gene variations significantly influence response rates to antiviral treatment in chronic hepatitis C.
  • Genetics is emerging as a crucial factor in personalized hepatitis C management.

Conclusions:

  • IL28B genotyping can help predict treatment outcomes in chronic hepatitis C.
  • Incorporating genetic information into clinical practice can optimize treatment strategies.
  • Genetics plays an increasingly vital role in the management of liver diseases like hepatitis C.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...